Concepedia

Ravi Visswanathan

RV

Statistics

Publications

6

Citations

409

H-Index

6

Active since

2016

Affiliations

Pfizer (United States)(Current)

Ravi Visswanathan is an author at Pfizer (United States) specializing in medicine, radiation oncology, and cell biology.

Top concepts

Publications per year

2016–2021

6

Publications

6

Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor

Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller et al. · Cancer Cell · 2021 · 172 citations

, , +10

Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer

Kevin D. Freeman‐Cook, Robert L. Hoffman, Douglas C. Behenna et al. · Journal of Medicinal Chemistry · 2021 · 112 citations · Full text

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Hengmiao Cheng, Suvi T. M. Orr, Simon Bailey et al. · Journal of Medicinal Chemistry · 2020 · 39 citations · Full text

Mechanistic insights on clearance and inhibition discordance between liver microsomes and hepatocytes when clearance in liver microsomes is higher than in hepatocytes

Christopher Keefer, George Chang, Anthony Carlo et al. · European Journal of Pharmaceutical Sciences · 2020 · 36 citations

, , +15

Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies

Mary E. Spilker, Xiaoying Chen, Ravi Visswanathan et al. · Clinical Cancer Research · 2016 · 35 citations · Full text

1–5 of 6